Ultragenyx Pharmaceutical (RARE) Price Target Cut to $88.00 by Analysts at Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price decreased by Wedbush from $90.00 to $88.00 in a research note released on Monday morning. Wedbush currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on the stock. Morgan Stanley reaffirmed an equal weight rating and set a $92.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday, September 10th. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $86.00 price target for the company in a research note on Wednesday, October 3rd. Robert W. Baird reissued a buy rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. Finally, Barclays reissued an overweight rating and set a $92.00 target price (up previously from $74.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $77.00.

RARE stock opened at $48.36 on Monday. The firm has a market cap of $2.44 billion, a PE ratio of -6.39 and a beta of 1.95. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $90.98.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.08) by $1.02. The firm had revenue of $12.79 million during the quarter, compared to the consensus estimate of $5.63 million. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. During the same quarter last year, the firm earned ($1.72) earnings per share. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -4.38 EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, Director William Aliski sold 19,550 shares of the firm’s stock in a transaction on Monday, October 8th. The shares were sold at an average price of $72.49, for a total value of $1,417,179.50. Following the completion of the sale, the director now directly owns 72,610 shares in the company, valued at $5,263,498.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $78.53, for a total transaction of $392,650.00. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock valued at $2,700,774 in the last three months. 8.40% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of RARE. Advisors Asset Management Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $181,000. Xact Kapitalforvaltning AB grew its holdings in shares of Ultragenyx Pharmaceutical by 49.7% during the first quarter. Xact Kapitalforvaltning AB now owns 6,623 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 2,200 shares during the last quarter. JBF Capital Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $384,000. Strs Ohio grew its holdings in shares of Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 4,300 shares during the last quarter. Finally, Pier 88 Investment Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $446,000. Institutional investors and hedge funds own 96.12% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Further Reading: Terms to Better Understand Call Options

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply